The company develops biomedical nanoparticle technology and products for research and treatment of human disease. They are developing NanoElectroPlex™, a proprietary tissue selective nanoparticle platform technology based on biodegradable macromolecular carriers.
ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and next generation antibodies and subunit vaccines through its proprietary Twin Cassette yeast system.
Arrayit Corporation empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
AuraSense's uniquely engineered nanoparticles possess unparalleled biocompatibility and versatility as therapeutics and as novel assays within live cells. They hold great promise for combating the most threatening diseases, including heart disease, cancer, and bacterial infection.
The company is a service partner for all aspects of oligonucleotides. It developed and produced the world's first and only translucent orthodontic systems using novel nanotechnology polymer composite products.
Biometic develops & manufactures bioactive scaffold systems for tissue engineering and bioreactor culture. These are optimized for a range of soft and hard tissue applications. As part of an ongoing collaborative and interdisciplinary development program, Biometic is helping advance fundamental understanding in tissue culture, biomechanics and medical research.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
A technology and service provider for specialized research in synthetic biology and related disciplines including the generation of new biomaterials for micro and nanofabrication processes, microelectronics, membranes, and catalytic surfaces.
The company's lead product in development is Amorphous Nano-Hydroxyapaite Powder. Nano-structured hydroxyapatite has several advantages over hydroxyapatite of larger particle size in its use in bone tissue engineering due to its higher surface area and consequently higher reactivity, which offers better cellular response. In addition, nano-sized hydroxyapatite is useful as an effective surface modification agent for binding numerous biological molecules.